Los puntos clave no están disponibles para este artículo en este momento.
"Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapy." Leukemia & Lymphoma, 61(14), pp. 3532–3533
Othman et al. (Wed,) studied this question.